Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Plus Pembrolizumab in Advanced Salivary Gland Cancers
NCT04209660Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2020
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib and pembrolizumab in adenoid cystic carcinoma (ACC) and salivary gland cancer (SGC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Best Overall Response Rate at 2 years. Started Jun 2020; status: active, not recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
adenoid cystic carcinoma (ACC)salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT04209660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209660.